Inhibition of anandamide hydrolysis attenuates nociceptor sensitization in a murine model of chemotherapy-induced peripheral neuropathy

Journal of Neurophysiology

Volumn 113, Issue 5, 2015, Pages 1501-1510

  Uhelski, Megan L ^a   Khasabova, Iryna A ^a   Simone, Donald A ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Allodynia; AM281; AM630; Cisplatin; Mouse; Tibial nerve; URB597

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N MORPHOLINO 1H PYRAZOLE 3 CARBOXAMIDE; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; ANANDAMIDE; CANNABINOID 1 RECEPTOR; CISPLATIN; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; ENDOCANNABINOID; FATTY ACID AMIDASE; HYDROLASE; AMIDASE; AMIDE; ARACHIDONIC ACID DERIVATIVE; BENZAMIDE DERIVATIVE; CANNABINOID RECEPTOR ANTAGONIST; CARBAMIC ACID DERIVATIVE; CYCLOHEXYL CARBAMIC ACID 3'-CARBAMOYLBIPHENYL-3-YL ESTER; FATTY-ACID AMIDE HYDROLASE; INDOLE DERIVATIVE; IODOPRAVADOLINE; MORPHOLINE DERIVATIVE; PYRAZOLE DERIVATIVE;

ALLODYNIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CHEMOTHERAPY; EVOKED RESPONSE; HYDROLYSIS; MALE; MOUSE; NERVE FIBER; NONHUMAN; PAIN RECEPTOR; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RECEPTOR SENSITIVITY; SENSITIZATION; SIGNAL TRANSDUCTION; TIBIAL NERVE; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; INJURIES; METABOLISM; NOCICEPTION; NONMYELINATED NERVE; PATHOPHYSIOLOGY; PERIPHERAL NERVOUS SYSTEM DISEASES; PHYSIOLOGY; SKIN;

AMIDOHYDROLASES; ANIMALS; ARACHIDONIC ACIDS; BENZAMIDES; CANNABINOID RECEPTOR ANTAGONISTS; CARBAMATES; CISPLATIN; ENDOCANNABINOIDS; HYDROLYSIS; INDOLES; MALE; MICE; MORPHOLINES; NERVE FIBERS, UNMYELINATED; NOCICEPTION; NOCICEPTORS; PERIPHERAL NERVOUS SYSTEM DISEASES; POLYUNSATURATED ALKAMIDES; PYRAZOLES; SKIN;

EID: 84923885045     PISSN: 00223077     EISSN: 15221598     Source Type: Journal    
DOI: 10.1152/jn.00692.2014     Document Type: Article

References (71)

1. Agarwal N, Pacher P, Tegeder I, Amaya F, Constantin CE, Brenner GJ, Rubino T, Michalski CW, Marsicano G, Monory K, Mackie K, Marian C, Batkai S, Parolaro D, Fischer MJ, Reeh P, Kunos G, Kress M, Lutz B, Woolf CJ, Kuner R. Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors. Nat Neurosci 10: 870–879, 2007.
2. Ahluwalia J, Urban L, Bevan S, Nagy I. Anandamide regulates neuropeptide release from capsaicin-sensitive primary sensory neurons by activating both the cannabinoid 1 receptor and the vanilloid receptor 1 in vitro. Eur J Neurosci 17: 2611–2618, 2003.
3. Ahluwalia J, Urban L, Capogna M, Bevan S, Nagy I. Cannabinoid 1 receptors are expressed in nociceptive primary sensory neurons. Neuroscience 100: 685–688, 2000.
4. Ali Z, Ringkamp M, Hartke TV, Chien HF, Flavahan NA, Campbell JN, Meyer RA. Uninjured C-fiber nociceptors develop spontaneous activity and a-adrenergic sensitivity following L6 spinal nerve ligation in monkey. J Neurophysiol 81: 455–466, 1999.
5. Bhagra A, Rao RD. Chemotherapy-induced neuropathy. Curr Oncol Rep 9: 290–299, 2007.
6. Bridges D, Rice AS, Egertova M, Elphick MR, Winter J, Michael GJ. Localisation of cannabinoid receptor 1 in rat dorsal root ganglion using in situ hybridisation and immunohistochemistry. Neuroscience 119: 803–812, 2003.
7. Burns TL, Ineck JR. Cannabinoid analgesia as a potential new therapeutic option in the treatment of chronic pain. Ann Pharmacotherapy 40: 251–260, 2006.
8. Cain DM, Khasabov SG, Simone DA. Response properties of mechanoreceptors and nociceptors in mouse glabrous skin: an in vivo study. J Neurophysiol 85: 1561–1574, 2001a.
9. Cain DM, Wacnik PW, Eikmeier L, Beitz A, Wilcox GL, Simone DA. Functional interactions between tumor and peripheral nerve in a model of cancer pain in the mouse. Pain Med 2: 15–23, 2001b.
10. Campbell JN, Meyer RA. Mechanisms of neuropathic pain. Neuron 52: 77–92, 2006.
11. Carozzi VA, Renn CL, Bardini M, Fazio G, Chiorazzi A, Meregalli C, Oggioni N, Shanks K, Quartu M, Serra MP, Sala B, Cavaletti G, Dorsey SG. Bortezomib-induced painful peripheral neuropathy: an electrophysiological, behavioral, morphological and mechanistic study in the mouse. PLoS One 12: e72995, 2013.
12. Cata JP, Weng HR, Dougherty PM. Behavioral and electrophysiological studies in rats with cisplatin-induced chemoneuropathy. Brain Res 1230: 91–98, 2008.
13. Cencioni MT, Chiurchiù V, Catanzaro G, Borsellino G, Bernardi G, Battistini L, Maccarrone M. Anandamide suppresses proliferation andcytokine release from primary human T-lymphocytes mainly via CB2 receptors. PLoS One 5: e8688, 2010.
14. Cherny NI, Thaler HT, Friedlander-Klar H, Lapin J, Foley KM, Houde R, Portenoy RK. Opioid responsiveness of cancer pain syndromes caused by neuropathic or nociceptive mechanisms: a combined analysis of controlled, single-dose studies. Neurology 44: 857–861, 1994.
15. Diaz-Rubio E, Sastre J, Zaniboni Labianca RA, Cortes-Funes H, de Braud F, Boni C, Benavides M, Dallavalle G, Homerin M. Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: A phase II multicentric study. Ann Oncol 9: 105–108, 1998.
16. Dworkin RH, Backonja M, Rowbotham MC, Allen RR, Argoff CR, Bennett GJ, Bushnell C, Farrar JT, Galer BS, Haythornthwaite JA, Hewitt DJ, Loeser JD, Max MB, Saltarelli M, Schmader KE, Stein C, Thompson D, Turk DC, Wallace MS, Watkins LR, Weinstein SM. Advances in neuropathic pain. Arch Neurol 60: 1524–1534, 2003.
17. Elmes SJ, Jhaveri MD, Smart D, Kendall DA, Chapman V. Cannabinoid CB2 receptor activation inhibits mechanically evoked responses of wide dynamic range dorsal horn neurons in naive rats and in rat models of inflammatory and neuropathic pain. Eur J Neurosci 20: 2311–2320, 2004.
18. Fox A, Kesingland A, Gentry C, McNair K, Patel S, Urban L, James I. The role of central and peripheral cannabinoid1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain. Pain 9: 91–100, 2001.
19. Fischbach T, Greffrath W, Nawrath H, Treede RD. Effects of anandamide and noxious heat on intracellular calcium concentration in nociceptive drg neurons of rats. J Neurophysiol 98: 929–938, 2007.
20. Gill JS, Windebank AJ. Cisplatin-induced apoptosis in rat dorsal root ganglion neurons is associated with attempted entry into the cell cycle. J Clin Invest 101: 2842–2850, 1998.
21. Guindon J, Beaulieu P. Antihyperalgesic effects of local injections of anandamide, ibuprofen, rofecoxib and their combinations in a model of neuropathic pain. Neuropharmacology 50: 814–823, 2006.
22. Guindon J, Desroches J, Beaulieu P. The antinociceptive effects of intraplantar injections of 2-arachidonoyl glycerol are mediated by cannabinoid CB2 receptors. Br J Pharmacol 150: 693–701, 2007.
23. Hamers FP, Gispen WH, Neijt JP. Neurotoxic side effects of cisplatin. Eur J Cancer 27: 372–376, 1991.
24. Hohmann AG. Spinal and peripheral mechanisms of cannabinoid antinociception: behavioral, neurophysiological and neuroanatomical perspectives. Chem Phys Lipids 121: 173–190, 2002.
25. Hori K, Ozaki N, Suzuki S, Sugiura Y. Upregulations of P2X3 and ASIC3 involve in hyperalgesia induced by cisplatin administration in rats. Pain 149: 393–405, 2010.
26. Huang H, Zhu L, Reid BR, Drobny GP, Hopkins PB. Solution structure of a cisplatin-induced DNA cross-link. Science 270: 1842–1845, 1995.
27. Jerman JC, Gray J, Brough SJ, Ooi L, Owen D, Davis JB, Smart D. Comparison of effects of anandamide at recombinant and endogenous rat vanilloid receptors. Br J Anaesth 89: 882–887, 2002.
28. Jhaveri MD, Richardson D, Kendall DA, Barrett DA, Chapman V. Analgesic effects of fatty acid amide hydrolase inhibition in a rat model of neuropathic pain. J Neurosci 26: 13318–13327, 2006.
29. Jordan P, Carmo-Fonseca M. Molecular mechanisms involved in cisplatin cytotoxicity. Cell Mol Life Sci 57: 1229–1235, 2000.
30. Joseph EK, Chen X, Bogen O, Levine JD. Oxaliplatin acts on IB4-positive nociceptors to induce an oxidative stress-dependent acute painful peripheral neuropathy. J Pain 9: 463–472, 2008.
31. Kautio AL, Haanpaa M, Saarto T, Kalso E. Amitriptyline in the treatment of chemotherapy-induced neuropathic symptoms. J Pain Symptom Manage 35: 31–39, 2008.
32. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 7: 573–584, 2007.
33. Khasabova IA, Chandiramani A, Harding-Rose C, Simone DA, Seybold VS. Increasing 2-arachidonoyl glycerol signaling in the periphery attenuates mechanical hyperalgesia in a model of bone cancer pain. Pharmacol Res 64: 60–67, 2011.
34. Khasabova IA, Khasabov S, Paz J, Harding-Rose C, Simone DA. Cannabinoid type-1 receptor reduces pain and neurotoxicity produced by chemotherapy. J Neurosci 32: 7091–7101, 2012.
35. Khasabova IA, Khasabov SG, Harding-Rose C, Coicou LG, Seybold BA, Lindberg AE, Steevens CD, Simone DA, Seybold VS. A decrease in anandamide signaling contributes to the maintenance of cutaneous mechanical hyperalgesia in a model of bone cancer pain. J Neurosci 28: 11141–11152, 2008.
36. Koltzenburg M, Kees S, Budweiser S, Ochs G, Toyka KV. The properties of unmyelinated nociceptive afferents change in a painful chronic constriction neuropathy. In: Proceedings of the 7th World Congress on Pain, Progress in Pain Research and Management, edited by Gebhart GF, Hammond DL, Jensen TS. Seattle, WA: IASP Press, 1994, vol. 2, p. 511–522.
37. Krarup-Hansen A, Helweg-Larsen S, Schmalbruch H. Neuronal involvement in cisplatin neuropathy: prospective clinical and neurophysiological studies. Brain 130: 1076–1088, 2007.
38. Kupczyk P, Reich A, Szepietowski JC. Cannabinoid system in the skin-a possible target for future therapies in dermatology. Exp Dermatol 18: 669–679, 2009.
39. Latremoliere A, Woolf CJ. Central sensitization: a generator of pain hypersensitivity by central neural plasticity. J Pain 10: 895–926, 2009.
40. McDonald ES, Randon KR, Knight A, Windebank AJ. Cisplatin preferentially binds to DNA in dorsal root ganglion neurons in vitro and in vivo: A potential mechanism for neurotoxicity. Neurobiol Dis 18: 305–313, 2005.
41. McWhinney SR, Goldberg RM, McLeod HL. Platinum neurotoxicity pharmacogenetics. Mol Cancer Ther 8: 10–16, 2009.
42. Melck D, Bisogno T, De Petrocellis L, Chuang H, Julius D, Bifulco M, Di Marzo V. Unsaturated long-chain N-acyl-vanillyl-amides (N-AVAMs): vanilloid receptor ligands that inhibit anandamide-facilitated transport and bind to CB1 cannabinoid receptors. Biochem Biophys Res Commun 262: 275–284, 1999.
43. Melli G, Taiana M, Camozzi F, Triolo D, Podini P, Quattrini A, Taroni F, Lauria G. Alpha-lipoic acid prevents mitochondrial damage and neurotoxicity in experimental chemotherapy neuropathy. Exp Neurol 214: 276–284, 2008.
44. Moreira FA, Grieb M, Lutz B. Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression. Best Pract Res Clin Endocrinol Metab 23: 133–144, 2009.
45. Olah Z, Karai L, Iadarola MJ. Anandamide activates vanilloid receptor 1 (VR1) at acidic pH in dorsal root ganglia neurons and cells ectopically expressing VR1. J Biol Chem 276: 31163–31170, 2001.
46. Petrosino S, Di Marzo V. FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels. Curr Opin Invest Drugs 11: 51–62, 2010.
47. Potenzieri C, Brink TS, Simone DA. Excitation of cutaneous C nociceptors by intraplantar administration of anandamide. Brain Res 1268: 38–47, 2009.
48. Price TJ, Patwardhan A, Akopian AN, Hargreaves KM, Flores CM. Modulation of trigeminal sensory neuron activity by the dual cannabinoidvanilloid agonists anandamide, N-arachidonoyl-dopamine and arachidonyl-2-chloroethylamide. Br J Pharmacol 141: 1118–1130, 2004.
49. Quastoff S, Hartung HP. Chemotherapy-induced peripheral neuropathy. J Neurol 249: 9–17, 2002.
50. Raff MC, Whitmore AV, Finn JT. Axonal self-destruction and neurodegeneration. Science 296: 868-871, 2002.
51. Rao RD, Michalak JC, Sloan JA, Loprinzi CL, Soori GS, Nikcevich DA, Warner DO, Novotny P, Kutteh LA, Wong GY. Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: A phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3). Cancer 110: 2110–2118, 2007.
52. Rice AS, Farquhar-Smith WP, Nagy I. Endocannabinoids and pain: spinal and peripheral analgesia in inflammation and neuropathy. Prostaglandins Leukot Essent Fatty Acids 66: 243–256, 2002.
53. Richardson PG, Briemberg H, Jagannath S, Wen PY, Barlogie B, Berenson J, Singhal S, Siegel DI, Schuster M, Srkalovic G, Alexanian R, Rajkumar SV, Limentani S, Alsina M, Orlowski RZ, Najarian K, Esseltine D, Anderson KC, Amato AA. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 24: 3113–3120, 2006.
54. Roberts LA, Christie MJ, Connor M. Anandamide is a partial agonist at native vanilloid receptors in acutely isolated mouse trigeminal sensory neurons. Br J Pharmacol 137: 421–428, 2002.
55. Robinson CR, Zhang H, Dougherty PM. Altered discharges of spinal neurons parallel the behavioral phenotype shown by rats with bortezomib related chemotherapy induced peripheral neuropathy. Brain Res 1574: 6–13, 2014.
56. Shim B, Kim DW, Kim BH, Nam TS, Leem JW, Chung JM. Mechanical and heat sensitization of cutaneous nociceptors in rats with experimental peripheral neuropathy. Neuroscience 132: 193–201, 2005.
57. Smart D, Gunthorpe MJ, Jerman JC, Nasir S, Gray J, Muir AI, Chambers JK, Randall AD, Davis JB. The endogenous lipid anandamide is a fullagonist at the human vanilloid receptor (hVR1). Br J Pharmacol 129: 227–230, 2000.
58. Ta LE, Bieber AJ, Carlton SM, Loprinzi CL, Low PA, Windebank AJ. Transient receptor potential vanilloid 1 is essential for cisplatin-induced heat hyperalgesia in mice. Mol Pain 6: 15, 2010.
59. Ta LE, Espeset L, Podratz J, Windebank AJ. Neurotoxicity of oxaliplatin and cisplatin for dorsal root ganglion neurons correlates with platinum-DNA binding. Neurotoxicity 27: 992–1002, 2006.
60. Tal M, Eliav E. Abnormal discharge originates at the site of nerve injury in experimental constriction neuropathy (CCI) in the rat. Pain 64: 511–518, 1996.
61. Tanner KD, Reichling DB, Levine JD. Nociceptor hyper-responsiveness during vincristine-induced painful peripheral neuropathy in the rat. J Neurosci 18: 6480–6491, 1998.
62. Tognetto M, Amadesi S, Harrison S, Creminon C, Trevisani M, Carreras M, Matera M, Geppetti P, Bianchi A. Anandamide excites central terminals of dorsal root ganglion neurons via vanilloid receptor-1 activation. J Neurosci 21: 1104–1109, 2001.
63. Walker JM, Huang SM. Cannabinoid analgesia. Pharmacol Ther 95: 127–135, 2002.
64. Walker JM, Strangman NM, Huang SM. Cannabinoids and pain. Pain Res Manag 6: 74, 2001.
65. Weng HR, Cordella JV, Dougherty PM. Changes in sensory processing in the spinal dorsal horn accompany vincristine-induced hyperalgesia and allodynia. Pain 103: 131–138, 2003.
66. Wolf S, Barton D, Kottschade L, Grothey A, Loprinzi C. Chemotherapyinduced peripheral neuropathy: prevention and treatment strategies. Eur J Cancer 44: 1507–1515, 2008.
67. Woolf CJ Ma Q. Nociceptors-noxious stimulus detectors. Neuron 55: 353–364, 2007.
68. Xiao WH, Bennett GJ. Chemotherapy-evoked neuropathic pain: abnormal spontaneous discharge in A-fiber and C-fiber primary afferent neurons and its suppression by acetyl-L-carnitine. Pain 135: 262–270, 2008.
69. Zhang JM, Song XJ, LaMotte RH. Enhanced excitability of sensory neurons in rats with cutaneous hyperalgesia produced by chronic compression of the dorsal root ganglion. J Neurophysiol 82: 3359–3366, 1999.
70. Zimmerman M. Ethical guidelines for investigation of experimental pain in conscious animals. Pain 16: 109–110, 1983.
71. Zygmunt PM, Petersson J, Anderson DA, Chuang H, Sorgard M, Di Marzo V, Julius D, Hogestatt ED. Vanilloid receptors in sensory nerves mediate the vasodilator action of anandamide. Nature 400: 452–457, 1999.